Is Atrasentan currently included in the scope of medical insurance reimbursement?

Atrasentan (Atrasentan) is a selective endothelinA receptor antagonist, mainly used to treat primary IgA nephropathy. It is one of the first drugs of its kind in the world to be approved for this indication. Its mechanism of action is to reduce the glomerular inflammatory response by blocking the endothelin signaling pathway, thereby significantly reducing proteinuria levels and slowing down the progression of renal function deterioration. The drug has been approved by the USFDA202411 an>Accelerated approval, trade name: Vanrafia, for the treatment of adult patients with primary IgA nephropathy associated with proteinuria.

As of July 2025, atrasentan has not been officially approved for marketing in mainland China, nor has it been included in the national medical insurance directory. Although Novartis has submitted a marketing application to China's National Medical Products Administration (NMPA) and has been included in the priority review channel, the marketing approval process is still progressing. Drugs usually need to go through a post-marketing pharmacoeconomic evaluation and national medical insurance negotiation process to enter the medical insurance catalog, which means that even if they are approved for marketing, it will take a while to determine whether they will be included in medical insurance.

At present, patients in China cannot purchase atrasentan through formal channels. If you need medicine, you can only obtain it by participating in relevant clinical trials, or consider purchasing drugs overseas. It is worth noting that even if purchased through overseas channels, the cost is relatively high. Because the drug is an innovative drug and there is no generic version, the financial burden is relatively heavy for the patient's family. Therefore, the issue of medical insurance coverage is of great significance to the patient.

Taken together, atrasentan is a new targeted drug that has the potential to change the treatment landscape of IgA kidney disease. Its domestic approval and medical insurance progress have attracted widespread attention in the industry. Once approved and included in medical insurance, it will greatly improve patient accessibility and medication compliance. It is recommended that patients and their families pay close attention to the relevant developments of the National Food and Drug Administration and the National Medical Insurance Bureau, and at the same time consult specialists for the latest medication information and alternative treatment options.

Reference materials:https://www.drugs.com/